FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine

To compare effectiveness of onabotulinumtoxinA and topiramate for chronic migraine (CM) prevention.

[1]  S. Tepper,et al.  Effects of onabotulinumtoxinA treatment for chronic migraine on common comorbidities including depression and anxiety , 2019, Journal of Neurology, Neurosurgery, and Psychiatry.

[2]  G. Guyatt,et al.  Optimising first- and second-line treatment strategies for untreated major depressive disorder — the SUN☺D study: a pragmatic, multi-centre, assessor-blinded randomised controlled trial , 2018, BMC Medicine.

[3]  R. Lipton,et al.  Identifying Natural Subgroups of Migraine Based on Comorbidity and Concomitant Condition Profiles: Results of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study , 2018, Headache.

[4]  P. Nikolaidis,et al.  The effect of myofascial release and microwave diathermy combined with acupuncture versus acupuncture therapy in tension‐type headache patients: A pragmatic randomized controlled trial , 2018, Physiotherapy research international : the journal for researchers and clinicians in physical therapy.

[5]  J. Sørensen,et al.  Longer term effectiveness of inpatient multidisciplinary rehabilitation on health-related quality of life in MS patients: a pragmatic randomized controlled trial – The Danish MS Hospitals Rehabilitation Study , 2017, Multiple sclerosis.

[6]  A. Straube,et al.  Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe , 2017, Cephalalgia : an international journal of headache.

[7]  S. Powers,et al.  Trial of Amitriptyline, Topiramate, and Placebo for Pediatric Migraine , 2017, The New England journal of medicine.

[8]  D. Dodick,et al.  Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis , 2016, Cephalalgia : an international journal of headache.

[9]  Mark W. Green,et al.  Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache , 2016, Neurology.

[10]  C. Lundqvist,et al.  Brief intervention by general practitioners for medication-overuse headache, follow-up after 6 months: a pragmatic cluster-randomised controlled trial , 2016, Journal of Neurology.

[11]  C. Witt,et al.  Effectiveness of app-based relaxation for patients with chronic low back pain (Relaxback) and chronic neck pain (Relaxneck): study protocol for two randomized pragmatic trials , 2014, Trials.

[12]  Amit G Singal,et al.  A Primer on Effectiveness and Efficacy Trials , 2014, Clinical and Translational Gastroenterology.

[13]  R. Ohrbach,et al.  The International Classification of Headache Disorders, 3rd edition (beta version) , 2013, Cephalalgia : an international journal of headache.

[14]  Russell E. Glasgow,et al.  What Does It Mean to Be Pragmatic? Pragmatic Methods, Measures, and Models to Facilitate Research Translation , 2013, Health education & behavior : the official publication of the Society for Public Health Education.

[15]  G. Oster,et al.  Adherence with Migraine Prophylaxis in Clinical Practice , 2012, Pain practice : the official journal of World Institute of Pain.

[16]  M. Ferrari,et al.  A proactive approach to migraine in primary care: a pragmatic randomized controlled trial , 2012, Canadian Medical Association Journal.

[17]  S. Aurora,et al.  OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Analyses of the 56‐Week PREEMPT Clinical Program , 2011, Headache.

[18]  B. D'avanzo,et al.  The GiSAS study: rationale and design of a pragmatic randomized controlled trial on aripiprazole, olanzapine and haloperidol in the long-term treatment of schizophrenia. , 2011, Contemporary clinical trials.

[19]  N. Patsopoulos.  A pragmatic view on pragmatic trials , 2011, Dialogues in clinical neuroscience.

[20]  D. A. van der Windt,et al.  Effectiveness of manual therapy for chronic tension-type headache: A pragmatic, randomised, clinical trial , 2011, Cephalalgia : an international journal of headache.

[21]  H. Diener,et al.  OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial , 2010, Cephalalgia : an international journal of headache.

[22]  H. Diener,et al.  OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial , 2010, Cephalalgia : an international journal of headache.

[23]  R. Lipton,et al.  Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[24]  N. Mathew,et al.  A Double‐Blind Comparison of OnabotulinumtoxinA (BOTOX®) and Topiramate (TOPAMAX®) for the Prophylactic Treatment of Chronic Migraine: A Pilot Study , 2009, Headache.

[25]  J. Olesen.  The International Classification of Headache Disorders , 2008, Headache.

[26]  H. Diener,et al.  Topiramate Reduces Headache Days in Chronic Migraine: A Randomized, Double-Blind, Placebo-Controlled Study , 2007, Cephalalgia : an international journal of headache.

[27]  R. Lipton,et al.  Efficacy and Safety of Topiramate for the Treatment of Chronic Migraine: A Randomized, Double‐Blind, Placebo‐Controlled Trial , 2007, Headache.

[28]  J. Saper,et al.  Topiramate for migraine prevention: a randomized controlled trial. , 2004, JAMA.

[29]  J. Lellouch,et al.  EXPLANATORY AND PRAGMATIC ATTITUDES IN THERAPEUTICAL TRIALS , 2003 .